Plain-English translation of NCT07062549 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new imaging agent called , which is combined with a special scan (called SPECT/CT) to help doctors find kidney cancer in your body. The medication is a radioactive tracer — a tiny amount of radioactive material — that is designed to attach to kidney cancer cells and make them visible on the scan. Researchers want to learn whether this new imaging approach can accurately detect and locate kidney cancer tumors.
Current imaging methods don't always find all kidney cancer in the body, which can make treatment planning difficult. This trial is testing whether the medication can improve doctors' ability to detect kidney cancer and help guide better treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you are enrolled, you will receive an injection of the new imaging medication and then undergo a SPECT/CT scan to see how well it detects your kidney cancer. The study is designed for a small group of patients — only 6 people total — so researchers can carefully monitor safety and effectiveness. Your blood work and overall health will be checked before you can participate.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment target
~6 participants
Started
January 2022
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yasser Ged, MBBS
Johns Hopkins University SKCCC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.